Advertisement
This European conference is important as Delcath continues to expandawareness of the company's Percutaneous Hepatic Perfusion (PHP) technology andthe clinical results of this innovative treatment for cancers in the liver.The Global Healthcare Conference is an opportunity to get the attention of newinstitutional investors, and to provide a forum for discussion with medicaltrade media outside of the U.S. Domestic interest in the System continues toincrease following the recent release of updated results from a Phase II studyof neuroendocrine tumors, which adds to the growing body of data indicatingthat Delcath's treatment is a viable option for patients diagnosed withinoperable liver tumors.
Advertisement
The presentation will be webcast live and can be accessed by visiting ourwebsite at www.delcath.com. The webcast will be archived for ninety days.
About Delcath Systems, Inc.
Delcath Systems is a developmental stage company testing its percutaneousperfusion technology for the isolated delivery of high doses of therapeuticand chemotherapeutic agents. The Delcath System is currently being tested inPhase III and Phase II clinical trials for the treatment of hepatocellularcarcinoma and metastatic tumors in the liver, including melanomas,neuroendocrine tumors and adenocarcinomas. The Company's intellectual propertyportfolio currently consists of twenty-eight patents on a worldwide basisincluding the U.S., Europe, Asia and Canada. For more information, pleasevisit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safeharbor for forward-looking statements made by the Company or on its behalf.This news release contains forward-looking statements, which are subject tocertain risks and uncertainties that can cause actual results to differmaterially from those described. Factors that may cause such differencesinclude, but are not limited to, uncertainties relating to our ability tosuccessfully complete Phase III clinical trials and secure regulatory approvalof our current or future drug-delivery system and uncertainties regarding ourability to obtain financial and other resources for any research, developmentand commercialization activities. These factors, and others, are discussedfrom time to time in our filings with the Securities and Exchange Commission.You should not place undue reliance on these forward-looking statements, whichspeak only as of the date they are made. We undertake no obligation topublicly update or revise these forward-looking statements to reflect eventsor circumstances after the date they are made.
SOURCE Delcath Systems, Inc.
